BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1216 related articles for article (PubMed ID: 30528609)

  • 1. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L; Huang R; Liu S; Huang S; Jiang C
    Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-Assembled Indomethacin Dimer Nanoparticles Loaded with Doxorubicin for Combination Therapy in Resistant Breast Cancer.
    Wang X; Cheng X; He L; Zeng X; Zheng Y; Tang R
    ACS Appl Mater Interfaces; 2019 Aug; 11(32):28597-28609. PubMed ID: 31314480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
    Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
    J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylated nano-graphene oxide as a nanocarrier for delivering mixed anticancer drugs to improve anticancer activity.
    Pei X; Zhu Z; Gan Z; Chen J; Zhang X; Cheng X; Wan Q; Wang J
    Sci Rep; 2020 Feb; 10(1):2717. PubMed ID: 32066812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of a charge-conversional dendrimer enhances antitumor efficacy of conventional chemotherapy.
    Cao J; Wang C; Guo L; Xiao Z; Liu K; Yan H
    Eur J Pharm Biopharm; 2018 Jun; 127():371-377. PubMed ID: 29499301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.
    Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L
    Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of Poria cocos extract and doxorubicin as an 'all-in-one' nanocarrier to combat breast cancer multidrug resistance during chemotherapy.
    Li Y; Li X; Lu Y; Chaurasiya B; Mi G; Shi D; Chen D; Webster TJ; Tu J; Shen Y
    Nanomedicine; 2020 Jan; 23():102095. PubMed ID: 31669856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells,
    Pishavar E; Ramezani M; Hashemi M
    Drug Dev Ind Pharm; 2019 Dec; 45(12):1931-1939. PubMed ID: 31609130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
    Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
    Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Characterization of a Poly(amido amine) Modified Magnetic Nanocarrier for Controlled Delivery of Doxorubicin.
    Xu S; Wu J; Jiang W; Tian R
    J Nanosci Nanotechnol; 2016 Feb; 16(2):1363-9. PubMed ID: 27433587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
    Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
    Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy.
    Lai PS; Lou PJ; Peng CL; Pai CL; Yen WN; Huang MY; Young TH; Shieh MJ
    J Control Release; 2007 Sep; 122(1):39-46. PubMed ID: 17628166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin.
    Wang J; Ma W; Guo Q; Li Y; Hu Z; Zhu Z; Wang X; Zhao Y; Chai X; Tu P
    Int J Nanomedicine; 2016; 11():5851-5870. PubMed ID: 27853369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release.
    Thanh VM; Nguyen TH; Tran TV; Ngoc UP; Ho MN; Nguyen TT; Chau YNT; Le VT; Tran NQ; Nguyen CK; Nguyen DH
    Mater Sci Eng C Mater Biol Appl; 2018 Jan; 82():291-298. PubMed ID: 29025661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.